John F de Groot

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma
    John de Groot
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Oncotarget 3:1036-48. 2012
  2. doi request reprint High-dose antiangiogenic therapy for glioblastoma: less may be more?
    John F de Groot
    Brain Tumor Center and Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 17:6109-11. 2011
  3. pmc Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
    John F de Groot
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:4872-81. 2011
  4. doi request reprint Improving the prognosis for patients with glioblastoma: the rationale for targeting Src
    John de Groot
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 431, Houston, TX 77030 4009, USA
    J Neurooncol 95:151-63. 2009
  5. doi request reprint Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas
    John F de Groot
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 14:279-85. 2008
  6. doi request reprint Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    J F de Groot
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 90:89-97. 2008
  7. doi request reprint Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation
    John F de Groot
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 88:121-33. 2008
  8. ncbi request reprint The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo
    John F de Groot
    The Brain Tumor Center, Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:1934-40. 2005
  9. pmc Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study
    John F de Groot
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:2689-95. 2011
  10. pmc Neutrophils promote the malignant glioma phenotype through S100A4
    Ji Liang
    Authors Affiliations Departments of Neuro Oncology, Neurosurgery, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 20:187-98. 2014

Research Grants

Collaborators

Detail Information

Publications35

  1. pmc Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma
    John de Groot
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Oncotarget 3:1036-48. 2012
    ....
  2. doi request reprint High-dose antiangiogenic therapy for glioblastoma: less may be more?
    John F de Groot
    Brain Tumor Center and Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 17:6109-11. 2011
    ..The long-term efficacy of bevacizumab and other antiangiogenic agents is limited, however, because of the rapid development of resistance. Alternative dosing approaches may be one mechanism of prolonging therapeutic efficacy...
  3. pmc Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept
    John F de Groot
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 17:4872-81. 2011
    ..We investigated potential blood-based markers associated with radiographic changes to aflibercept, which binds VEGF and placental growth factor (PlGF) in patients with recurrent glioblastoma...
  4. doi request reprint Improving the prognosis for patients with glioblastoma: the rationale for targeting Src
    John de Groot
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 431, Houston, TX 77030 4009, USA
    J Neurooncol 95:151-63. 2009
    ..This review will focus on dasatinib, the most advanced Src inhibitor being tested in glioblastoma, which is currently in phase I/II trials in this setting...
  5. doi request reprint Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas
    John F de Groot
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer J 14:279-85. 2008
    ..The impact of cytotoxic chemotherapy on the efficacy of bevacizumab and the effect of this therapy on overall survival are important questions that remain to be answered...
  6. doi request reprint Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
    J F de Groot
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Neurooncol 90:89-97. 2008
    ..Carboplatin plus erlotinib is well tolerated but has modest activity in unselected patients. Future trials should be stratified based on optimal molecular or clinical characteristics...
  7. doi request reprint Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation
    John F de Groot
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Neurooncol 88:121-33. 2008
    ..These results suggest that AMPA receptors are abundantly expressed in high-grade gliomas and gene silencing of the GluR1 AMPA receptor subunit results in abrogation of AMPA-mediated signaling and tumor growth...
  8. ncbi request reprint The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo
    John F de Groot
    The Brain Tumor Center, Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:1934-40. 2005
    ..Further studies will improve our knowledge of the role of glutamate in glioma growth and may provide useful prognostic information and alternative therapeutic targets for the treatment of glioma...
  9. pmc Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study
    John F de Groot
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:2689-95. 2011
    ..This single-arm phase II study evaluated the efficacy of aflibercept (VEGF Trap), a recombinantly produced fusion protein that scavenges both VEGF and placental growth factor in patients with recurrent malignant glioma...
  10. pmc Neutrophils promote the malignant glioma phenotype through S100A4
    Ji Liang
    Authors Affiliations Departments of Neuro Oncology, Neurosurgery, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Clin Cancer Res 20:187-98. 2014
    ..Currently, the mechanisms by which this resistance occurs are not well understood...
  11. ncbi request reprint Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma
    Dimpy Koul
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Unit 1002, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 5:637-44. 2006
    ..This decrease in cell growth stemmed from the induction of apoptosis. Collectively, these results provide a strong rationale for the pharmacologic targeting of Akt for the treatment of gliomas...
  12. doi request reprint Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
    Agda K Lucio-Eterovic
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:4589-99. 2009
    ....
  13. doi request reprint Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition
    Yuji Piao
    Brain Tumor Center, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 19:4392-403. 2013
    ..The aim of the present study was to identify mechanisms responsible for glioblastoma resistance to antiangiogenic therapy...
  14. ncbi request reprint Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma
    Dimpy Koul
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Unit 100, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Mol Cancer Ther 4:1681-8. 2005
    ..Thus, blocking the ILK/Akt pathway is a potential strategy for molecular targeted therapy for gliomas...
  15. pmc VEGF Trap induces antiglioma effect at different stages of disease
    Candelaria Gomez-Manzano
    Department of Neuro Oncology, Unit 1002, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:940-5. 2008
    ..Finally, our results indicate that the clinical success of VEGF Trap may depend on a prolonged treatment in combined therapy aiming to simultaneously inhibit angiogenesis and tumor invasion...
  16. pmc Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
    John F de Groot
    Brain Tumor Center, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Neuro Oncol 12:233-42. 2010
    ..This model mimicked many of the histopathologic findings from the human cases and will augment the discovery of alternative or additive therapies to prevent this type of tumor recurrence in clinical practice...
  17. pmc Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation
    Christian L Barney
    Corresponding Author Anita Mahajan, MD, Department of Radiation Oncology, Unit 97, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030
    Neuro Oncol 16:303-9. 2014
    ..Proton craniospinal irradiation (p-CSI) has been proposed to reduce side effects associated with CSI. We evaluated acute toxicities and preliminary clinical outcomes in a series of adults treated with p-CSI...
  18. pmc Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype
    Yuji Piao
    Brain Tumor Center, Department of Neuro Oncology, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Neuro Oncol 14:1379-92. 2012
    ..Collectively, our results demonstrate a more prolonged decrease in tumor vascularity with bevacizumab than with sunitinib, associated with a delay in the development of hypoxia and sustained reduction of infiltrated myeloid cells...
  19. pmc Moving toward molecular classification of diffuse gliomas in adults
    Brett J Theeler
    Department of Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Neurology 79:1917-26. 2012
    ....
  20. pmc Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
    Vinay K Puduvalli
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Neuro Oncol 10:216-22. 2008
    ..The results also provide support for similar strategies using combination therapies with newer targeted antiangiogenic agents to generate effective therapies against malignant gliomas...
  21. ncbi request reprint New molecular targets in malignant gliomas
    John F de Groot
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Curr Opin Neurol 20:712-8. 2007
    ..The purpose of this review is to provide an update on the identification of novel molecular targets in neurooncology and their translation into clinical practice...
  22. pmc Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
    Yuji Piao
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas Y P, S Y P, N T, J F d G Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas V H Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts B D S, D L F
    Neuro Oncol 18:1230-41. 2016
    ..Evasive revascularization and the recruitment of TIE2-expressing macrophages (TEMs) are also triggered by anti-VEGF therapy...
  23. pmc Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy
    Ji Liang
    Brain Tumor Center, Department of Neuro Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Oncotarget 6:31479-92. 2015
    ..Determining the mechanism of treatment failure of the VEGF monoclonal antibody bevacizumab for malignant glioma would provide insight into approaches to overcome therapeutic resistance...
  24. pmc Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma
    Marta Penas-Prado
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas M P P, M D G, V A L, J F d G, C A C, M E L, W K A Y, M R G Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas K R H General Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas M J F, L W L Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas A M Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas K D A Department of Neurosurgery, Kaiser Permanente Redwood City Medical Center, Redwood City, California V A L Department of Neurological Surgery, Ohio State University Comprehensive Cancer Center, Columbus, Ohio V K P Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah H C Atlanta Regional Community Clinical Oncology Program, Georgia Cancer Specialists, Canton, Georgia G V R Department of Neurosciences, Medical University of South Carolina Brain and Spine Tumor Program, Charleston, Cancer Centre
    Neuro Oncol 17:266-73. 2015
    ..Chemoradiation, followed by adjuvant temozolomide, is the standard treatment for newly diagnosed glioblastoma. Adding other active agents may enhance treatment efficacy...
  25. doi request reprint Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution
    Jacob J Mandel
    Department of Neurology, Baylor College of Medicine, One Baylor Plaza, MS NB302, Houston, TX, 77030, USA
    J Neurooncol 120:597-605. 2014
    ..However, patients receiving chemotherapy/targeted therapy and radiation were younger and this may have influenced survival. Given the overall poor outcomes, improved therapeutic approaches are needed for glioblastoma patients with LMD. ..
  26. pmc Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma
    Jacob J Mandel
    Department of Neurology, Baylor College of Medicine, One Baylor Plaza, MS NB302, Houston, TX, 77030, USA
    J Neurooncol 129:147-54. 2016
    ..19.32 months for IDH1 mutated GB (p = 0.14). IDH1 mutation status was not predictive of PFS6 or RR in recurrent GB trials for this data set. However, further examination in larger randomized prospective studies is needed. ..
  27. pmc Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma
    Soon Young Park
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 7:26793-805. 2016
    ..Finally, high expression of CLK2 protien was significantly associated with worse patient survival. These findings suggest that CLK2 plays a critical role in controlling the cell cycle and survival of glioblastoma via FOXO3a/p27. ..
  28. pmc A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
    Shiao Pei Weathers
    Department of Neuro Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 431, Houston, TX, 77030, USA
    J Neurooncol 129:487-94. 2016
    ..Further studies are needed to better identify such subgroups that may most benefit from the combination treatment. ..
  29. pmc Pregnancy and glial brain tumors
    Shlomit Yust-Katz
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas S Y K, J F d G, M D A, C A C, M R G, T S A Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas D L, J W, Y Y Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas A M
    Neuro Oncol 16:1289-94. 2014
    ..Improvements in brain tumor treatments have led to an increase in the number of young women with brain tumors who are now considering pregnancy. The aim of this study is to evaluate the influence of pregnancy on brain tumor biology...
  30. pmc Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma
    Aaron P Brown
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 86:277-84. 2013
    ..Efficacy and acute toxicity of proton craniospinal irradiation (p-CSI) were compared with conventional photon CSI (x-CSI) for adults with medulloblastoma...
  31. ncbi request reprint Multigene sets for clinical application in glioma
    John F de Groot
    Brain Tumor Center, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Natl Compr Canc Netw 9:449-56; quiz 457. 2011
    ..Identification of relevant biomarkers, especially when coupled with clinical trials of newer targeted therapies, will enable better patient stratification and individualization of treatment for patients with glioma...
  32. pmc Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models
    Soon Young Park
    Department of Neuro Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Mol Cancer Ther 15:2187-97. 2016
    ..Moreover, recombinant POSTN increased GSC invasion. Collectively, our findings suggest that POSTN plays an important role in glioma invasion and resistance to antiangiogenic therapy. Mol Cancer Ther; 15(9); 2187-97. ©2016 AACR. ..
  33. doi request reprint Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: a population-based analysis
    Gary V Walker
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:4538-44. 2012
    ..The purpose of this study was to assess what factors influence radiation therapy (RT) utilization in patients with glioblastoma and to ascertain how patterns of care have changed over time...
  34. pmc Dapsone induced methemoglobinemia in a patient with glioblastoma
    Julie G Walker
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Neurooncol 94:149-52. 2009
    ..Furthermore, given the toxicities of TMP-SMZ and dapsone, further work is needed to determine the threshold CD4(+) count at which empiric prophylaxis should be initiated...
  35. pmc Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium
    Ramsis K Benjamin
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:65-74. 2004
    ..In doing so we provide a rationale for the use of this technology by a National Cancer Institute consortium, New Approaches to Brain Tumor Therapy, to measure levels of drugs in brain tissue as part of phase 1 trials...

Research Grants1

  1. Predictive Markers of Glioblastoma Response to VEGF Trap
    John de Groot; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..